AMES Test: Self-Administered Cognitive Screening

The Automated Memory and Executive Screening (AMES), introduced by Huang, Mei, Ye, and Guo (2023), is a self-administered cognitive screening instrument designed to detect mild cognitive impairment (MCI) in primary-care settings. The tool addresses a familiar bottleneck in dementia care: clinician-administered screens like the MMSE and MoCA require trained staff and 10–15 minutes per patient, which means most older adults at risk of MCI are never screened until symptoms are obvious enough to prompt referral. AMES is one of a growing set of computerised tools designed to push that screening earlier, into the patient’s hands, and into routine primary-care visits.

What AMES measures

AMES is administered on a tablet or computer with no clinician supervision required. It assesses three cognitive domains commonly affected in early MCI: memory (immediate and delayed recall), language (object naming, semantic fluency), and executive function (working memory and processing speed). Total administration time is roughly 15 minutes. The output is a single composite score with cutoffs for “normal,” “objective subjective cognitive decline” (obj-SCD), and MCI.

The design reflects two practical constraints in primary-care screening. First, the test must be short enough to fit into a routine visit. Second, it must run without supervision because primary-care clinicians do not have the time or training to administer a standardised neuropsychological battery for every older adult on their list. The self-administered format trades off some control over administration conditions for a large gain in scalability.

How well does it perform?

Huang et al. (2023) validated AMES on 189 participants from primary-care clinics, comprising healthy controls, individuals with obj-SCD, and individuals with diagnosed MCI. Two performance benchmarks emerged from the study.

For detecting MCI versus normal cognition, AMES achieved an area under the ROC curve (AUC) of 0.88, with 86% sensitivity and 80% specificity at the optimal cutoff. These are the headline numbers and they sit comfortably within the range typically reported for established screening tools in similar settings. For detecting obj-SCD — a more subtle, pre-MCI category — performance was weaker: AUC 0.78, sensitivity 89%, specificity 63%. The drop in specificity for obj-SCD means that a meaningful fraction of cognitively normal individuals will screen positive at this threshold, and any deployment will need a downstream confirmatory step before any clinical decision is made.

Convergent validity was demonstrated by strong correlations with established cognitive scales used in the same sample. Test–retest reliability was acceptable for a screening instrument designed to be used at routine intervals.

How does AMES compare to MMSE, MoCA, and SAGE?

Three reference points anchor the screening landscape. The Mini-Mental State Examination (Folstein, Folstein, & McHugh, 1975) is the original 30-point bedside screen. It is fast, free, and ubiquitous, but its sensitivity to MCI (as opposed to overt dementia) is poor — many studies report MMSE sensitivity below 50% for MCI detection. The Montreal Cognitive Assessment (Nasreddine et al., 2005) was developed specifically to fix that gap; it is broadly considered the modern gold standard for MCI screening, with sensitivity typically reported in the 80–100% range against neuropsychological reference diagnoses. Both MMSE and MoCA require a trained administrator.

The closest peer to AMES is the Self-Administered Gerocognitive Examination (Scharre et al., 2010), a paper-based self-administered screen that has been deployed at scale in primary-care settings, including community screening events. SAGE established that self-administration is clinically viable for cognitive screening — AMES extends that approach into a digital, automated, scoring-on-the-spot format, which removes scoring inconsistency and shortens turnaround.

The trade-off across these instruments is consistent: tools that require clinician administration buy more control over conditions and clearer scoring, while self-administered tools buy reach and scalability at the cost of some administration variance. AMES sits firmly on the scalability end of that spectrum. Its 0.88 MCI AUC is comparable to MoCA’s reported performance in equivalent samples, but AMES achieves it without consuming clinician time.

What is the test actually screening for?

The clinical target is mild cognitive impairment as defined by Petersen (2004): cognitive performance below age- and education-adjusted norms in one or more domains, but without the functional impairment that would warrant a dementia diagnosis. MCI is clinically important because roughly half of MCI cases progress to dementia within five years, while the remainder either stabilise or revert to normal cognition. Screening tools cannot diagnose MCI on their own — that requires neuropsychological assessment and clinical judgement — but they can flag the patients who warrant deeper workup.

AMES is one input into that decision tree, not the decision itself. A positive AMES result means “this patient warrants further evaluation,” not “this patient has MCI.” This distinction matters because the specificity numbers above imply non-trivial false-positive rates: at the obj-SCD threshold, roughly 37% of cognitively normal individuals in the validation sample screened positive. In a real-world primary-care population, that translates to a substantial number of patients who receive unnecessary follow-up — the standard tradeoff for high sensitivity in early-detection contexts.

Limitations and what is still unknown

The Huang et al. (2023) validation has the limitations typical of a single-cohort instrument paper. The sample was Chinese and primary-care-recruited, with educational and demographic distributions that may not generalise to other populations or healthcare systems. Cultural and linguistic adaptation will require fresh validation work before AMES can be deployed at scale in non-Chinese settings. Cross-sectional validation also tells us nothing about predictive validity over time — whether a positive AMES at age 65 reliably predicts MCI conversion or progression to dementia by age 70 is an open empirical question.

The other open question is the meaning of the obj-SCD signal. Subjective cognitive decline — a person’s own report that their memory is worse than it used to be — is a known risk factor for subsequent MCI and dementia, but the precise clinical interpretation of an “objective” version derived from a screening test is still being worked out in the literature. AMES detects something at this threshold; what exactly that something means for an individual patient’s prognosis is not yet settled.

Where AMES fits in primary-care practice

The realistic role for an instrument like AMES is as the first filter in a stepped-care model: routine screening at primary-care visits, downstream specialist referral for positives, and clinical workup (including neuropsychological assessment, neuroimaging, and increasingly blood-based biomarkers) for those who continue to show signs of cognitive impairment after referral. The value of pushing this first step into the patient’s hands — rather than relying on opportunistic clinician-administered screening — is that it dramatically increases the proportion of older adults who get screened at all. The cost is a higher absolute number of false positives, which is acceptable as long as the downstream workup capacity exists to absorb them.

Used this way, AMES contributes to the broader strategy of preventing or delaying cognitive decline through early identification of at-risk individuals, alongside lifestyle modification and management of vascular and metabolic risk factors. It is not a magic bullet, and the clinical evidence base will need to grow before it can be incorporated into formal screening guidelines. But it is a credible step in the direction the field has been moving for two decades: cognitive screening that scales.

Frequently asked questions

What does AMES stand for?

Automated Memory and Executive Screening. It is a self-administered cognitive screening tool introduced by Huang, Mei, Ye, and Guo in Assessment in 2023.

How long does AMES take?

Roughly 15 minutes, administered by the patient on a tablet or computer with no clinician supervision required. The score is computed automatically.

Is AMES a diagnostic test for MCI or dementia?

No. AMES is a screening tool. A positive AMES result means a patient warrants further evaluation; an MCI or dementia diagnosis requires comprehensive neuropsychological assessment and clinical judgement, not a screening score alone.

How does AMES compare to the MoCA?

Both tools target MCI detection and report similar AUC values (around 0.88) in their respective validation samples. The MoCA requires a trained administrator and 10–15 minutes of clinician time per patient. AMES is self-administered and removes that staff bottleneck, at the cost of less control over administration conditions.

Can a normal AMES score rule out cognitive decline?

Not entirely. The validation reported 86% sensitivity for MCI, meaning roughly 14% of MCI cases were missed at the optimal cutoff. A normal score lowers the probability of MCI but does not exclude it — clinical judgement and follow-up over time are still needed when symptoms persist or progress. Age- and education-adjusted norms (see average IQ by age) provide additional context for interpreting cognitive scores in older adults.